RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Purpose
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Instructions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Condition
- Pain
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Study candidate is scheduled to be trialed, on-label, with a commercially approved Boston Scientific neurostimulation system for pain, per local directions for use - Signed a valid, IRB/EC-approved informed consent form - 18 years of age or older
Exclusion Criteria
- Contraindicated for Boston Scientific neurostimulation system - Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Boston Scientific SCS Systems | Subjects permanently implanted with a Boston Scientific neurostimulation systems |
|
Recruiting Locations
Greenwood Village, Colorado 80111
Clermont, Florida 34711
Clermont, Florida 34711
Gainesville, Florida 32608
New Orleans, Louisiana 70115
Shreveport, Louisiana 71105
Boston, Massachusetts 02115
Ann Arbor, Michigan 48108
The Bronx, New York 10461
Eugene, Oregon 97401
Trevose, Pennsylvania 19053
Greenville, South Carolina 29601
Corpus Christi, Texas 78414
More Details
- NCT ID
- NCT01719055
- Status
- Recruiting
- Sponsor
- Boston Scientific Corporation
Detailed Description
The study is a prospective, multi-center, global, post-market study of Boston Scientific neurostimulation systems for pain. The study treatment will consist of neurostimulation trial therapy with any commercially approved Boston Scientific Corporation neurostimulator for pain. Positive trials, subjects with a successful trial outcome, may progress to permanent implant of a neurostimulation system. Individualization of neurostimulation therapy for pain will be determined according to investigator discretion and site routine care, and in accordance with inclusion and exclusion criteria.